Phase 3 Readout~month
Phase 3 Topline: Evaluation of Dabocemagene Autoficel (D-Fi; FCX-007; Genetically Modified Autologous Human Dermal Fi
- Indication
- Dystrophic Epidermolysis Bullosa
Other upcoming events for CSTL
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.